Company Update - MorphoSys AG
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
May 2016 Company Update
Safe Harbor This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations and the availability of financing. These and other risks and uncertainties are detailed in the Company’s Annual Report. © MorphoSys AG, Company Update - May 2016 2
MorphoSys at a Glance
MorphoSys is developing a pipeline of truly differentiated
therapeutic antibodies built using proprietary technologies
Munich, Germany-based biopharmaceutical company
The industry’s largest antibody therapeutic pipeline assembled using
proprietary technologies:
104 active therapeutic programs
26 antibodies in clinical trials
Growing portfolio of attractive proprietary assets
Strong balance sheet with recurring cash-flows supports growing investment
in R&D
Successful track-record of partnering world-wide
Listed on the German TecDAX
© MorphoSys AG, Company Update - May 2016 3
The MorphoSys Pipeline
26 Clinical Product Candidates, 104 Total
Most advanced development stage
Program Partner Target Disease Area Discovery Preclinic Phase 1 Phase 2 Phase 3
Bimagrumab (BYM338) Novartis ActRIIB Musculoskeletal diseases
Guselkumab (CNTO1959) Janssen IL23p19 Psoriasis
Gantenerumab Roche Amyloid-ß Alzheimer’s disease
MOR208 - CD19 ALL, CLL, NHL
MOR202 - CD38 Multiple myeloma
MOR103/GSK3196165 GSK GM-CSF Inflammation
Anetumab Ravtansine (BAY94-9343) Bayer Mesothelin (ADC) Solid tumors
BHQ880 Novartis DKK-1 Multiple myeloma
BPS804 Mereo/Novartis Sclerostin Brittle bone syndrome
CNTO3157 Janssen - Inflammation
CNTO6785 Janssen - Inflammation
LFG316 Novartis C5 Eye diseases
LJM716 Novartis HER3 Cancer
Tarextumab (OMP-59R5) OncoMed Notch 2 Solid tumors
VAY736 Novartis BAFF-R Inflammation
MOR209/ES414 Emergent PSMA/CD3 Prostate cancer
MOR106 Galapagos - Inflammation
BAY1093884 Bayer TFPI Hemophilia
BI–836845 BI IGF-1 Solid tumors
NOV–7 Novartis - Eye diseases
NOV–8 Novartis - Inflammation
NOV-9 Novartis - Diabetic eye diseases
NOV-10 Novartis - Cancer
NOV-11 Novartis - Blood disorders
PF-05082566 Pfizer 4-1BB Solid tumors
Vantictumab (OMP-18R5) OncoMed Fzd 7 Solid tumors
MOR107 (LP2) - AT2-R Fibrosis
Immuno-oncology program Merck - Cancer
90 Partnered Discovery Programs
Immuno-oncology program Immatics - Cancer
6 MOR programs - - Various
13 MOR Programs
1 Outlicensed Program
In addition, 24 partnered programs in pre-clinic, and 45 partnered programs in discovery
© MorphoSys AG, Company Update - May 2016 4
The MOR Portfolio
5 Clinical Product Candidates, 14 Total
Program Indication Target Discovery Preclinic Phase 1 Phase 2 Phase 3
Unpartnered
MOR208 DLBCL FTD, orphan status US & EU
CD19
CLL Orphan status US & EU
MOR202 Multiple myeloma CD38
MOR107 Fibrosis AT2-R
Immuno-oncology MHC-associated
Cancer
program peptides
6 Programs Various Various
Co-development & co-promotion
MOR209/ES414 Prostate cancer PSMA / CD3
(Emergent)
MOR106 Inflammation Undisclosed
(Galapagos)
Immuno-oncology
program Cancer Undisclosed
(Merck Serono)
Outlicensed to GSK
RA
MOR103/ GM-CSF
GSK3196165 Osteoarthritis of
the hand
© MorphoSys AG, Company Update - May 2016 5
MOR208
First- & Best-in Class Potential
CD19 is an ideal target in NHL because
CD19 is broadly and homogeneously expressed
Across different NHL subtypes incl. DLBCL and CLL
CD19 conveys a survival signal for B cells
Via B cell receptor signaling
CD19 expression seems to be preserved
Even after pretreatments targeting B cells
MOR208 is an Fc-enhanced, humanized IgG1 antibody
targeting CD19
Fc modification leads to dramatically enhanced B cell
depletion by
Antibody dependent cellular cytotoxicity (ADCC)
Antibody dependent cell phagocytosis (ADCP) ADCC
Direct cytotoxicity
Straightforward manufacturing
Strong pre-clinical support for combo therapy
© MorphoSys AG, Company Update - May 2016 6
MOR208 in R/R CLL
Superior to Other CD19 and CD20 MAbs
anti-CD19 MAbs anti-CD20 MAbs
50%
ORR [%]*
40% 38%
30%
30% 24% 23%
20%
13%
10%
0%
MOR208 MEDI-551 Obinutuzumab Ofatumumab Rituximab
12mg/kg phase 1/2 phase 2 phase 3 (n=110)
(n=16) 12mg/kg (n=20) (n=196)
(n=26)
PFS 15 14
[months] 10.7
10 Sources:
8 MOR208: Woyach et al., Blood 2014
MEDI-551: Forero-Torres et al. ASH 2013
5.5 Obinutuzumab: Cartron et al., Blood 2014
5 Ofatumumab: Byrd et al., NEJM 2014
Rituximab: Furman et al., NEJM 2014
*IWCLL Criteria: Hallek et al., 2008
NR
0 [NR – not reported]
© MorphoSys AG, Company Update - May 2016 7
MOR208 in R/R NHL
Strong Single Agent Efficacy
Response Rate
DLBCL iNHL incl. FL
in evaluable patients*
n=25 n=40
n (%)
Overall Response (ORR) 9 (36%) 12 (30%)
Complete response (CR) 2 (8%) 5 (13%)
Partial response (PR) 7 (28%) 7 (18%)
Stable disease (SD) 5 (20%) 21 (53%)
*Investigator assessed Jurczak et al., Abstract #1528, ASH 2015
© MorphoSys AG, Company Update - May 2016 8
MOR208 in R/R NHL
Very Promising Duration of Response
DLBCL
Duration of Response:
Longest: 20 months+
Patients with CR or PR
12 months: 67%
Duration of response
DLBCL, n=9
Indolent NHL,* n=12
Ongoing response, n=9
Time to response, n=21
0.0 5.0 10.0 15.0 20.0 25.0
Months
* Includes follicular lymphoma and other indolent NHLs
DLBCL, diffuse large B-cell lymphoma; NHL, non-Hodgkin’s lymphoma. Jurczak et al., Abstract #1528, ASH 2015
© MorphoSys AG, Company Update - May 2016 9MOR208
Comprehensive Clinical Development Plan
Indication 2016 2017 2018
NHL MOR208
(12 mg/kg); N=92
DLBCL
L-MIND: MOR208 (12mg/kg) + lenalidomide; 2nd line R/R; N=80
B-MIND: Safety evaluation leading into anticipated pivotal study
MOR208 (12 mg/kg) + bendamustine vs.
rituximab + bendamustine; 2nd line R/R; N~320
CLL
COSMOS: MOR208 (12mg/kg) + combo partner; BTKi-failures
MOR208 (9mg/kg) + lenalidomide; R/R, naive & Richter’s Transformation
MOR208 + ibrutinib in ibrutinib failures } N=80 (Ohio State Univ. IIT)
Phase 2
Phase 2/3
IIT: Investigator-initiated trial
© MorphoSys AG, Company Update - May 2016 10MOR202
A Novel Antibody for Multiple Myeloma
Fully human monoclonal HuCAL IgG1 antibody
Targeting a unique epitope of CD38
Inducing potent immune effector mechanisms
ADCC and ADCP
One of only three CD38 antibodies in clinical
development
Strongly synergistic with IMiDs and proteasome
inhibitors in pre-clinical models
ADCC = Antibody-Dependent Cell-Mediated Cytotoxicity; ADCP = Antibody-Dependent Cell-Mediated Phagocytosis;
CDC = Complement-Dependent cytotoxicity
© MorphoSys AG, Company Update - May 2016 11MOR202
Preliminary Phase 1/2a Data
SD
Single agent MOR202:
SD
PR ORR = 33%
PR MOR202 & IMiD combos:
MR Clinical benefit rate of 67%
Patients Treated
PR
VGPR MOR202 q1w + Dex cohorts
PR
4 mg/kg + Dex
SD
8 mg/kg + Dex
VGPR
SD
16 mg/kg + Dex
SD 8 mg/kg + POM/Dex
PD 8 mg/kg + LEN/Dex
PD Response recorded
SD Ongoing patients
0 10 20 30 40 50 60
Weeks
Data from patients treated with the clinically relevant dose regimens who received > 1 treatment cycle.
Dex, dexamethasone; LEN, Lenalidomide; MR, minor response; POM, Pomalidomide; PD, progressive disease; PR, partial
response; q1w, weekly; SD, stable disease; VGPR, very good partial response.
Raab et al, #3035, ASH 2015
© MorphoSys AG, Company Update - May 2016 12MOR202: Excellent Clinical Safety &
Convenience
MOR202 shows best-in-class infusion tolerability & infusion duration
MOR202 Daratumumab Isatuximab
6.5 h
Infusion time 2h (1st infusion) 4-6h
(3.5 h @ 3rd infusion)
Infusion reactions 6%
70-77% 52%
(IRRs) with Steroids (Grade 1 only)
MOR202: Raab et al., ASH 2015
Daratumumab: Lokhorst et al., NEJM 2015
Isatuximab: Martin et al., ASH 2015
© MorphoSys AG, Company Update - May 2016 13MOR202: Pre-clinical Data Suggest Advantage in
Durability of Response
MOR202 shows best-in-class difference between MM cell killing and NK cell preservation
CD38-expressing MM cell line CD38-expressing NK cells
50 40
% specific NK cell killing
35
40
% specific killing
30
30 25
20
20 15
10
10
5
0 0
MOR202 Daratumumab Isatuximab MOR202 Daratumumab Isatuximab
© MorphoSys AG, Company Update - May 2016 14Clinical Programs
from Partnered Discovery Alliances (I)
Program Partner Target Indication Phase 1 Phase 2 Phase 3
Bimagrumab Novartis ActRIIB sIBM (extension)
(BYM338) sIBM (long-term study)
Hip fracture surgery
Cachexia (COPD)
Sarcopenia (dose-ranging)
Sarcopenia (withdrawal extension study)
Guselkumab Janssen/J&J IL23p19 Psoriasis (VOYAGE 1)
(CNTO1959) Psoriasis (VOYAGE 2)
Psoriasis (NAVIGATE)
Pustular/Erythrodermic psoriasis
Moderate to severe plaque-type psoriasis
Palmoplantar pustulosis
Active psoriatic arthritis
Gantenerumab Roche Amyloid-ß Mild Alzheimer‘s disease
Prodromal Alzheimer‘s disease
Genetically predisposed
Safety, Tolerability, and Pharmacokinetics
Anetumab Ravtansine Bayer Mesothelin Mesothelioma (MPM)
(BAY94-9343) Solid tumors, with pemetrexed and cisplatin
Advanced malignancies (Japan)
Ovarian cancer, with doxorubicin
Solid tumors with hepatic/renal impairment
BHQ880 Novartis DKK-1 MM (renal insufficiency)
Smoldering MM
BPS804 Mereo/Novartis Sclerostin Osteoporosis
Hypophosphatasia (HPP)
Osteogenesis Imperfecta
CNTO3157 Janssen/J&J n.d. Asthma
Safety/Pharmacokinetic
CNTO6785 Janssen/J&J n.d. COPD
Rheumatoid arthritis
© MorphoSys AG, Company Update - May 2016 15Clinical Programs
from Partnered Discovery Alliances (II)
Program Partner Target Indication Phase 1 Phase 2 Phase 3
LFG316 Novartis C5 Age-related geographic atrophy
Geographic atrophy (combo with CLG561)
Panuveitis
Paroxysmal nocturnal hemoglobinuria
Transplant Associated Microangiopathy (TAM)
LJM716 Novartis HER3 ESCC (combo with BYL719)
HER2+ cancer (combo BYL719 & trastuzumab)
HER2+ cancer, combo with trastuzumab
Tarextumab Oncomed/GSK Notch 2 Small cell lung cancer (Pinnacle)
(OMP-59R5) Solid tumors
VAY736 Novartis BAFF-R Pemphigus vulgaris
Primary Sjögren‘s syndrome
Rheumatoid Arthritis
BAY1093884 Bayer TFPI Bleeding disorders
BI-836845 BI IGF-1 Solid tumors, Japanese patients
EGFR mutant NSCLC
Metastatic breast cancer
CRPC + enzalutamide
Advanced solid tumors
NOV-7 Novartis n.d. Eye disease
NOV-8 Novartis n.d. Inflammation
NOV-9 Novartis n.d. Diabetic eye disease
NOV-10 Novartis n.d. Cancer
NOV-11 Novartis n.d. Blood disorders
PF-05082566 Pfizer 4-1BB Advanced malignancies, with avelumab
Solid tumors, NHL (+rituximab)
Solid tumors, with PD-1i MK-3475
Advanced solid tumors, with mogamulizumab
Solid tumors, with PF04518600 (OX-40)
Vantictumab Oncomed/Bayer Fzd 7 Solid tumors
(OMP-18R5) Metastatc breast cancer
Pancreatic cancer (combo)
NSCL
© MorphoSys AG, Company Update - May 2016 16Guselkumab (CNTO1959)
A Janssen Anti-Inflammatory Program
Guselkumab
A HuCAL antibody specific for IL-23, does not bind IL-12
IL-23 blockade inhibits production of multiple cytokines
beyond IL-17A and preserves Th1 & Treg regulatory pathways
Being developed in psoriasis and psoriatic arthritis
Current Status
Six Phase 3 clinical trials ongoing
First Phase 3 data expected in 2016
Anticipated filing in 2016
Source: Jetten AM, Nucl Recept Signal, 2009
© MorphoSys AG, Company Update - May 2016 17Guselkumab (CNTO1959) Clinical Data Highest levels of durable skin clearance with less intensive dosing regimens vs. anti-IL-17 class Potential for similar safety profile vs. long-term blockade of IL-12 + 23 with STELARA® Potential for long-term, drug-free efficacy Data courtesy of Janssen © MorphoSys AG, Company Update - May 2016 18
Anetumab Ravtansine (BAY94-9343)
A Bayer Anti-Cancer Program
Anetumab Ravtansine
ADC comprising
HuCAL anti-mesothelin G1 antibody conjugated to
potent maytansinoid tubulin inhibitor DM4
In development for mesothelioma & other solid cancers
Pre-clinic
Anetumab ravtansine potently inhibited growth of
human mesothelioma models in vivo
Phase 1
Anetumab ravtansine 6.5 mg/kg IV Q3W was well
tolerated and showed efficacy in patients with
previously treated mesothelioma
Phase 2
Started Q1, 2016
Second-line, malignant pleural mesothelioma
Estimated enrollment 210
Antibody-drug conjugate anti-tumor therapy
(A) General mechanism of action
Data courtesy of Bayer Healthcare (B) Structure of anetumab ravtansine
© MorphoSys AG, Company Update - May 2016 19Pipeline Set to Deliver a Lot of Clinical Data
PHASE 3
Bimagrumab Guselkumab Bimagrumab
sIBM Psoriasis (VOYAGE 2) sIBM (extension)
Guselkumab Guselkumab Guselkumab
Psoriasis (VOYAGE 1) Psoriasis (NAVIGATE) Pustular/Erythrodermic Psoriasis
LFG316 Anetumab Ravtansine
PNH Mesothelioma (MPM)
LJM716 Bimagrumab MOR103/GSK3196165
+ trastuzumab Hip fracture surgery RA
LJM716 Bimagrumab MOR202
ESCC + BYL716 Sarcopenia (dose ranging) Multiple Myeloma
PHASE 2
MOR202 Guselkumab MOR208
Multiple Myeloma Psoriatic Arthritis CLL + combo
MOR208 LFG316 MOR208
CLL (IIT) Panuveitis DLBCL + lenalidomide
MOR208 LFG316 Tarextumab
NHL GA + CLG561 Small cell lung cancer
VAY736 LJM716 VAY736
Pemphigus Vulgaris + BYL716 + trastuzumab Primary Sjögren‘s Syndrome (PD)
Anetumab Ravtansine BI-836845
+ pemetrexed & cisplatin EGFR mutant NSCLC
Anetumab Ravtansine MOR106
Ovarian cancer + doxorubicin Inflammation
PHASE 1
Anetumab Ravtansine Anetumab Ravtansine MOR209
Advanced malignancies Solid tumors Prostate cancer
BI-836845 BAY-1093884 PF-05082566
Advanced solid tumors Bleeding disorders NHL + rituximab
Gantenerumab BI-836845 PF-05082566
Safety, Tolerability, & PK Metastatic breast cancer Advanced solid tumors + avelumab
LJM716 BI-836845 PF-05082566
+ trastuzumab CRPC + enzalutamide Solid tumors + MK-3475
2016 2017
Based on published information and MorphoSys estimates Partnered Discovery Programs MOR Programs Outlicensed programs
© MorphoSys AG, Company Update - May 2016 20Powerful Technology Base Ensures Pipeline
Sustainability
Innovative Targets Proprietary Platforms
GPCRs, ion channels Antibody library
Immune checkpoints
Protein optimization
Differentiated
drug candidates
MHC-presented, tumor-
associated peptides
Lantipeptides
Source of novel targets
© MorphoSys AG, Company Update - May 2016 21Financial Guidance 2016
Guidance
in EUR million 2015A Q1 2016
2016
Group Revenues 106.2 12.1 47 to 52
Proprietary R&D Expenses
56.6 14.6 76 to 83
(incl. Technology Development)
EBIT 17.2 -9.7 -58 to -68
Cash, cash equivalents & marketable securities
298.4 287.0
as well as other short-term and long-term financial assets
© MorphoSys AG, Company Update - May 2016 22Coming Up
Bimagrumab sIBM Data from pivotal trial and regulatory filing expected
Guselkumab Psoriasis Data from 3 pivotal trials and regulatory filing expected
MOR208 Phase 2 lenalidomide combo trial L-MIND starts
Phase 2 bendamustine combo trial B-MIND:
DLBCL
Safety evaluation to start mid 2016
Pivotal study planned for 2017
CLL Phase 2 idelalisib combo trial in planning
MOR202 MM Updated data from phase 1/2a trial at ASCO 2016
Continuation of phase 1 trial under amended protocol, clinical data
MOR209 Prostate cancer
in 2017
MOR106 Inflammation Start of phase 1 with Galapagos in H1 2016
MOR107 Fibrosis Start of phase 1 in Q4 2016
MOR103 Osteoarthritis Start of phase 1b/2a in osteoarthritis of the hand
RA Data from the phase 2b in RA in 2017
Pipeline Up to 5 new program starts
Around 5 clinical milestones
© MorphoSys AG, Company Update - May 2016 23APPENDIX © MorphoSys AG, Company Update - May 2016 24
MOR103/GSK3196165
Anti-inflammatory Program Licensed to GSK
MOR103/GSK3196165 % EULAR good/moderate response
HuCAL antibody specific for GM-CSF at 4 weeks: Rapid onset of action
80 Phase Ib/IIa study, n=96
% EULAR response
GM-CSF is important in every step of macrophage
production and infiltration in the tissues 60
Good magnitude of effect with fast onset of action and 40
long duration post treatment 20
Effect size appears similar to or greater than anti-TNF 0
Targeting the macrophage in early RA Placebo 0.3 mg/kg 1.0 mg/kg 1.5 mg/kg
Potential for early use to induce remission Week 4 Week 6 Week 8
Indications
Lead indication: Rheumatoid arthritis (RA) Behrens, et al. Ann Rheum Dis. 2015;74:1058-64
Potential for disease modification & analgesic activity in
hand osteoarthritis (HOA)
Current Status
BAROQUE (RA phase 2b) ongoing
Initial clinical read-out 2016
Phase 2 in hand osteoarthritis to start in 2016
© MorphoSys AG, Company Update - May 2016 25MOR209/ES414
A Novel Bi-specific Antibody for Prostate Cancer
Co-development Agreement with Emergent BioSolutions
Phase 1 clinical trial in mCRPC patients was started in March of 2015
Restructured Agreement with
Emergent BioSolutions
Adjustment of dosing regimen
and administration
Reduction of MorphoSys’s cost
sharing and reduced milestone
payments
Clinical development will continue in 2016 under an adapted clinical development plan.
© MorphoSys AG, Company Update - May 2016 26Covering Analysts Institution Contact Baader Helvea Dr. Bruno Bulic Commerzbank Mr. Daniel Wendorff Deutsche Bank Mr. Gunnar Romer Edison Mr. Maxim Jacobs Goldman Sachs Mr. Keyur Parekh Independent Research GmbH Mr. Bernhard Weininger J.P. Morgan Cazenove Mr. James Gordon Kempen & Co. Mr. Sachin Soni / Mr. Mark Pospisilik Landesbank Baden-Württemberg Mr. Timo Kürschner Oddo Seydler Mr. Igor Kim © MorphoSys AG, Company Update - May 2016 27
Thank You www.morphosys.com Dr. Claudia Gutjahr-Löser Head of Corporate Communications & IR Phone +49 (0)89 / 899 27-404 Fax +49 (0)89 / 899 27-5404 Email investors@morphosys.com HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla® , Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG. Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.
You can also read
